|
[1] National Workshop on Fatty Liver and Alcoholic Liver Disease, Chinese Society of Hepatology, Chinese Medical Association;Fatty Liver Expert Committee, Chinese Medical Doctor Association. Guidelines of prevention and treatment for nonalcoholic fatty liver disease:A 2018 update[J]. J Clin Hepatol, 2018, 34 (5) :947-957. (in Chinese) 中华医学会肝病学分会脂肪肝和酒精性肝病学组, 中国医师协会脂肪性肝病专家委员会.非酒精性脂肪性肝病防治指南 (2018年更新版) [J].临床肝胆病杂志, 2018, 34 (5) :947-957.
|
|
[2] MANTOVANI A, DAURIZ M, BYRNE CD, et al. Association between nonalcoholic fatty liver disease and colorectal tumours in asymptomatic adults undergoing screening colonoscopy:A systematic review and meta-analysis[J]. Metabolism, 2018, 87:1-12.
|
|
[3] CHEN DZ, JI FY, XU QM, et al. Interaction of smoking and metabolic syndrome in increasing the recurrence risk of colorectal cancer in a Chinese male cohort:A retrospective study[J]. Sci Rep, 2018, 8 (1) :972.
|
|
[4] CHEN J, BIAN D, ZANG S, et al. The association between nonalcoholic fatty liver disease and risk of colorectal adenoma and cancer incident and recurrence:A meta-analysis of observational studies[J]. Expert Rev Gastroenterol Hepatol, 2019, 13 (4) :385-395.
|
|
[5] CHEN KL, MADAK-ERDOGAN Z. Estrogens and female liver health[J]. Steroids, 2018, 133:38-43.
|
|
[6] PALMISANO BT, ZHU L, STAFFORD JM. Role of estrogens in the regulation of liver lipid metabolism[J]. Adv Exp Med Biol, 2017, 1043:227-256.
|
|
[7] NIE X, XIE R, TUO B. Effects of estrogen on the gastrointestinal tract[J]. Dig Dis Sci, 2018, 63 (3) :583-596.
|
|
[8] LUGARI S, MANTOVANI A, NASCIMBENI F, et al. Hypothyroidism and nonalcoholic fatty liver disease-a chance association?[J]. Horm Mol Biol Clin Investig, 2018.[Epub ahead of print]
|
|
[9] MANTOVANI A, GRANI G. Thyroid dysfunction and nonalcoholic fatty liver disease:We need new larger and well-designed longitudinal studies[J]. Dig Dis Sci, 2018, 63 (7) :1970-1976.
|
|
[10] EFSTATHIADOU ZA, KITA MD, POLYZOS SA. Thyroid dysfunction and non-alcoholic fatty liver disease[J]. Minerva Endocrinol, 2018, 43 (3) :367-376.
|
|
[11] CHAN YX, AIFONSO H, CHUBB SA, et al. Higher thyrotropin concentration is associated with increased incidence of colorectal cancer in older men[J]. Clin Endocrinol (Oxf) , 2017, 86 (2) :278-285.
|
|
[12] ZHANG YJ, LIU YT, YU XS. Predictive value of serum liver enzyme for the metabolic syndrome[J]. Chin J Med Offic, 2017, 45 (1) :82-85. (in Chinese) 张艳君, 刘奕婷, 于晓松.血清肝酶指标对代谢综合征预测价值[J].临床军医杂志, 2017, 45 (1) :82-85.
|
|
[13] AL-DAYYAT HM, RAYYAN YM, TAYYEM RF. Non-alcoholic fatty liver disease and associated dietary and lifestyle risk factors[J]. Diabetes Metab Syndr, 2018, 12 (4) :569-575.
|
|
[14] KATSIKI N, PEREZ-MARTINEZ P, ANAGNOSTIS P, et al. Is nonalcoholic fatty liver disease indeed the hepatic manifestation of metabolic syndrome?[J]. Curr Vasc Pharmacol, 2018, 16 (3) :219-227.
|
|
[15] ULAGANATHAN V, KANDIAH M, MOHD SHARIFF Z. A casecontrol study of the association between metabolic syndrome and colorectal cancer:A comparison of International Diabetes Federation, National Cholesterol Education Program Adults Treatment Panel III, and World Health Organization definitions[J]. J Gastrointest Oncol, 2018, 9 (4) :650-663.
|
|
[16] PAN S, HONG W, WU W, et al. The relationship of nonalcoholic fatty liver disease and metabolic syndrome for colonoscopy colorectal neoplasm[J]. Medicine (Baltimore) , 2017, 96 (2) :e5809.
|
|
[17] FUJII H, IMAJO K, YONEDA M, et al. HOMA-IR:An independent predictor of advanced liver fibrosis in nondiabetic non-alcoholic fatty liver disease[J]. J Gastroenterol Hepatol, 2019.[Epub ahead of print]
|
|
[18] MU W, CHENG XF, LIU Y, et al. Potential nexus of non-alcoholic fatty liver disease and type 2 diabetes mellitus:Insulin resistance between hepatic and peripheral tissues[J]. Front Pharmacol, 2019, 9:1566.
|
|
[19] WALKIEWICZ K, NOWAKOWSKA-ZAJDEL E, KOZIEL P, et al. The role of some ADAM-proteins and activation of the insulin growth factor-related pathway in colorectal cancer[J].Cent Eur J Immunol, 2018, 43 (1) :109-113.
|
|
[20] OBI K, RAMSEY M, HINTON A, et al. Insights into insulin resistance, lifestyle, and anthropometric measures of patients with prior colorectal cancer compared to controls:A National Health and Nutrition Examination Survey (NHANES) Study[J]. Curr Probl Cancer, 2018, 42 (2) :276-285.
|
|
[21] WADA S, YASUNAGA Y, OKA K, et al. Submucosal fat accumulation in human colorectal tissue and its association with abdominal obesity and insulin resistance[J]. United European Gastroenterol J, 2018, 6 (7) :1065-1073.
|
|
[22] IBRAHIMI M, MOOSSAVI M, MOJARAD EN, et al. Positive correlation between interleukin-1 receptor antagonist gene86bp VNTR polymorphism and colorectal cancer susceptibility:A case-control study[J]. Immunol Res, 2019, 67 (1) :151-156.
|
|
[23] RAZI S, BARADARAN NOVEIRY B, KESHAVARZ-FATHI M, et al. IL-17 and colorectal cancer:From carcinogenesis to treatment[J]. Cytokine, 2019, 116:7-12.
|
|
[24] YANG XL, SUN XM, ZHAO XH, et al. Expressions of IL-17E, IL-17F and their receptors in colorectal carcinoma tissue and their significances[J]. J Jilin Univ:Med Edit, 2018, 44 (3) :574-578. (in Chinese) 杨学良, 孙雪梅, 赵晓晖, 等. IL-17E和IL-17F及其受体在结直肠癌组织中的表达及其意义[J].吉林大学学报:医学版, 2018, 44 (3) :574-578. (in Chinese)
|
|
[25] GHAZI-KHANLOOSANI M, BANDEGI AR, KOKHAEI P, et al. CRP and LOX-1:A mechanism for increasing the tumorigenic potential of colorectal cancer carcinoma cell line[J].Pathol Oncol Res, 2018.[Epub ahead of print]
|
|
[26] MANDAL P. Molecular mechanistic pathway of colorectal carcinogenesis associated with intestinal microbiota[J]. Anaerobe, 2018, 49:63-70.
|
|
[27] MA C, ZHANG Q, GRETEN TF. Nonalcoholic fatty liver disease promotes hepatocellular carcinoma through direct and indirect effects on hepatocytes[J]. FEBSJ, 2018, 285 (4) :752-762.
|
|
[28] HOFFMANOVA I, SANCHEZ D, TUCKOVA L, et al. Celiac disease and liver disorders:From putative pathogenesis to clinical implications[J]. Nutrients, 2018, 10 (7) :e892.
|
|
[29] de FARIA GHETTI F, OLIVEIRA DG, de OLIVEIRA JM, et al.Influence of gut microbiota on the development and progression of nonalcoholic steatohepatitis[J]. Eur J Nutr, 2018, 57 (3) :861-876.
|
|
[30] MANTOVANI A, DAURIZ M, BYRNE CD, et al. Association between nonalcoholic fatty liver disease and colorectal tumours in asymptomatic adults undergoing screening colonoscopy:A systematic review and meta-analysis[J].Metabolism, 2018, 87:1-12.
|
|
[31] WU K, ZHAI MZ, WELTZIEN EK, et al. Non-alcoholic fatty liver disease and colorectal cancer survival[J]. Cancer Causes Control, 2019, 30 (2) :165-168.
|
|
[32] PENG J, CHEN Y, DONG XL, et al. Association between KRAS gene mutations and clinicopathological characteristics and prognosis of colorectal cancer patients[J]. Chin J Dig Surg, 2018, 17 (2) :143-147. (in Chinese) 彭健, 陈颖, 董先龙, 等. KRAS基因突变与结直肠癌患者临床病理特征及预后的关系[J].中华消化外科杂志, 2018, 17 (2) :143-147.
|
|
[33] DOLATKHAH R, SOMI MH, SHABANLOEI R, et al. Main risk factors association with proto-oncogene mutations in colorectal cancer[J]. Asian Pac J Cancer Prev, 2018, 19 (8) :2183-2190.
|
DownLoad: